Treatment of Claudication With a Peristaltic Pulse Pneumatic Device

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by White River Junction VAMC.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
NormaTec Industries LP
Information provided by:
White River Junction VAMC
ClinicalTrials.gov Identifier:
NCT01007604
First received: November 3, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted
  Purpose

The purpose of this study is to evaluate the efficacy of a non-invasive peristaltic pulse pneumatic device (PCD) in the treatment of intermittent claudication in patients having documented peripheral arterial disease (PAD). The pneumatic device to be studied is FDA approved for the treatment of venous disease. While anecdotal evidence exists supporting a decrease in claudication symptoms, there are no previously published data on studies employing this compression device in the treatment of arterial disease. The investigators' primary hypothesis is that patients randomized to the intervention arm of the trial will experience an increase in mean walking ability as compared to the group receiving medical standard of care.


Condition Intervention Phase
Intermittent Claudication
Device: Peristaltic pulse PCD
Other: Exercise and lifestyle counseling
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy Study of a Peristaltic Pulse Pneumatic Device in the Treatment of Claudication

Resource links provided by NLM:


Further study details as provided by White River Junction VAMC:

Primary Outcome Measures:
  • Peak walking time (in seconds) during a graded-protocol treadmill test [ Time Frame: initial; 3 months; 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Claudication onset time (in seconds) during a graded-protocol treadmill test [ Time Frame: initial; 3 months; six months ] [ Designated as safety issue: No ]
  • Walking Impairment Questionnaire, including pain subscale, speed subscale and stair climbing subscale [ Time Frame: initial; 3 months; 6 months ] [ Designated as safety issue: No ]
  • Ankle-Brachial Index (ABI) [ Time Frame: initial; 3 months; 6 months ] [ Designated as safety issue: No ]
  • Integumentary changes as evaluated by photographs of lower extremity hair pattern and great toenail growth [ Time Frame: initial; 3 months; 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: November 2009
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Exercise and lifestyle counselling
Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
Other: Exercise and lifestyle counseling
Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
Other Names:
  • Ambulatory exercise
  • Smoking cessation counseling
Experimental: PCD with peristaltic pulse waveform
Daily use for two hours
Device: Peristaltic pulse PCD
Daily use for two hours
Other Names:
  • NormaTec PCD
  • Exercise and lifestyle counselling

Detailed Description:

Peripheral arterial disease (PAD) is a common disorder, affecting 12% of adults older than 50 years of age. Approximately one third of these patients experience intermittent claudication, defined as pain in the thigh or calf muscles during walking and that resolves with rest. Lower extremity pain is often severe enough to significantly limit ambulation, forcing many patients to seek medical care. Current treatments include two FDA-approved medications, supervised walking programs, arterial angioplasty and/or stent placement, and open arterial bypass surgery. The problem is that noninvasive treatments are oftentimes ineffective, while invasive treatments are effective but expensive.

A non-invasive lower extremity treatment that has shown success in treating lymphedema and venous insufficiency will be studied during this protocol to assess its effects on claudication symptoms. Half of the participants in this prospective, single-center randomized controlled trial will be treated with a pneumatic compression device in a home treatment program, while half will receive standard medical therapy. If effective, potential benefits are high, providing relief of personal disability and avoidance of costly surgical intervention.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consistent claudication symptoms for at least 6 months
  • ABIs at rest as follows: 0.5>ABI<0.8 minimally on one leg

Exclusion Criteria:

  • Refuses to consent
  • Unlikely to be compliant with protocol
  • Unable to perform treadmill test
  • Current use of Cilostazol (Pletal) or Pentoxyphylline (Trental)
  • Lower extremity surgery or endovascular procedure within the last 3 months
  • Currently has a non-healing wound on either leg
  • DVT in the past 3 months
  • Unstable hypertension, angina, uncontrolled glucose levels
  • Participating in a supervised exercise regimen
  • Claudication medications regime changed within the last 3 months
  • Diagnosis of Raynaud's Disease
  • Requires a custom fabricated boot appliance
  • Single limb amputees meeting inclusion criteria may participate in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01007604

Contacts
Contact: Sharon R Besso, MS, ARNP 802-295-9363 ext 6390 sharon.besso@va.gov
Contact: Joseph P Duggan, DPM 802-295-9363 ext 5289 joseph.duggan@va.gov

Locations
United States, Vermont
White River Junction VAMC Not yet recruiting
White River Junction, Vermont, United States, 05009
Contact: Sharon R Besso, MS, ARNP    802-295-9363 ext 6390    sharon.besso@va.gov   
Contact: Joseph P Duggan, DPM    802-295-9363 ext 5289    joseph.duggan@va.gov   
Principal Investigator: Sharon R Besso, MS, ARNP         
Principal Investigator: Joseph P Duggan, DPM         
Sub-Investigator: Caroline Whittington, DPM         
Sponsors and Collaborators
White River Junction VAMC
NormaTec Industries LP
Investigators
Principal Investigator: Sharon R Besso, MS, ARNP White River Junction VAMC
Principal Investigator: Joseph P Duggan, DPM White River Junction VAMC
  More Information

No publications provided

Responsible Party: Sharon Besso, ARNP, White River Junction VAMC
ClinicalTrials.gov Identifier: NCT01007604     History of Changes
Other Study ID Numbers: 21975
Study First Received: November 3, 2009
Last Updated: November 3, 2009
Health Authority: United States: Federal Government

Keywords provided by White River Junction VAMC:
claudication
pneumatic compression device

Additional relevant MeSH terms:
Intermittent Claudication
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on August 27, 2014